Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25353198 | 1.00 | DRD4 (0.41) | DRD4ALDH1A1HTTDRD2ADRA1D | |
| SCHEMBL30454084 | 1.00 | DRD4 (0.41) | DRD4ALDH1A1HTTDRD2ADRA1D | |
| SCHEMBL30453495 | 1.00 | DRD4 (0.41) | DRD4ALDH1A1HTTDRD2ADRA1D | |
| SCHEMBL25354316 | 0.84 | ALDH1A1 (0.41) | DRD4ALDH1A1HTTMLNR | |
| SCHEMBL25355099 | 0.84 | ALDH1A1 (0.41) | DRD4ALDH1A1HTTMLNR | |
| SCHEMBL25353488 | 0.83 | CYP2D6 (0.46) | DRD4ALDH1A1HTTDRD2ADRA1D | |
| SCHEMBL25354841 | 0.83 | MEN1 (0.48) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL25353494 | 0.83 | CYP2D6 (0.46) | DRD4ALDH1A1HTTDRD2ADRA1D | |
| SCHEMBL25354844 | 0.83 | MEN1 (0.48) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL30453323 | 0.83 | CYP2D6 (0.46) | DRD4ALDH1A1HTTDRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250099481-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121713-A1 | BCL-2 INHIBITORS | NEW AVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | DRD4 835/4885ALDH1A1 3831/4885HTT 3042/4885 |
| US-20250099481-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | DRD4 1191/4885ALDH1A1 3478/4885HTT 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.